SK Pharmteco Expands Biocatalysis Capabilities with Prozomix Enzyme Toolkit
Event summary
- SK Pharmteco partners with Prozomix to integrate its Biocatalysis Enzyme Toolkit, featuring over 6,000 diverse native biocatalysts, into its small-molecule development and manufacturing services.
- The collaboration aims to enhance sustainable, efficient pharmaceutical processes by leveraging enzyme-based synthesis for complex API production.
- Prozomix’s enzyme diversity will be utilized across SK Pharmteco’s global R&D and manufacturing network in the U.S., Europe, and Asia.
- The partnership is expected to accelerate the transition from enzyme screening to full-scale enzyme production and drug manufacturing.
The big picture
The partnership aligns with the broader industry trend toward sustainable and efficient pharmaceutical manufacturing processes. As drug molecules become more complex, the use of enzymes offers a greener, more selective, and cost-effective alternative to traditional chemical synthesis. This collaboration positions SK Pharmteco to capitalize on the growing demand for innovative and sustainable solutions in the biopharmaceutical sector.
What we're watching
- Technology Integration
- How the integration of Prozomix’s enzyme toolkit will impact SK Pharmteco’s existing technology platforms and client offerings.
- Market Differentiation
- Whether the collaboration will solidify SK Pharmteco’s position as a multi-modality partner in the global biopharmaceutical industry.
- Execution Risk
- The pace at which SK Pharmteco can scale the use of biocatalysis across its global manufacturing network.
Related topics